Executive​/Senior Director, Medical Affairs

Executive/Senior Director, Medical Affairs Company Description

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by overcoming resistance in cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers.

Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to , and follow us on X or Linked In.

ORIC Pharmaceuticals is seeking a Senior/Executive Director, Medical Affairs, as an initial member of the Global Medical Affairs (GMA) team based in ORIC’s South San Francisco office. Reporting to the Head of Medical Affairs, this individual will be responsible for developing and executing the GMA strategy and tactical plans with a focus on launch readiness and life cycle management for therapies across prostate cancer, non‑small cell lung cancer (NSCLC), and potentially other tumor types.

The successful candidate will have a proven track record of developing and driving medical strategy for multiple assets with a focus on effectively analyzing and communicating key scientific data through publications, medical information, medical communications, congress activities as well as gathering insights through advisory boards, advocacy, and Key Opinion Leader (KOL) relationships. The candidate must work collaboratively with cross‑functional counterparts in Clinical Development and Operations, Regulatory, Research, Finance, Legal, and Commercial as well as other ORIC functional groups to design and implement a medical strategy for rinzimetostat in prostate cancer and enozertinib in NSCLC.

The ideal candidate will have background experience in biotech/biopharma, during both pre‑launch and post‑launch product phases, is an experienced and collaborative leader, highly effective communicator, entrepreneurial, solutions‑oriented, proactive, and scientifically driven.

• Build and lead key Global Medical Affairs (GMA) capabilities in areas such as medical communications, operations, field medical, and a robust independent scientific research assessment process.
• Facilitate the development and execution of the multi‑year US and global medical strategy and plan for rinzimetostat and enozertinib, including activities related to scientific engagement and communication, internal education, and patient advocacy.
• Lead integrated evidence generation planning in prostate, NSCLC and other disease areas of interest, including development/refinement of a publication strategy/plan, an evidence/RWD generation plan, and tactical plan as part of the overall GMA plan.
• Provide medical leadership in scientific engagement activities with key stakeholders through organizing and leading advisory boards, investigator interactions, congress activities, educational presentations and peer‑to‑peer discussions with the goal of exchanging and communicating scientific insights to internal teams to drive strategy.
• Lead the operations and oversight of medical affairs activities in key therapeutic areas while working cross‑functionally with multiple functional leaders to support pre‑launch/launch activities, and provide regular updates and support to management.
• Develop and execute a strategic plan for key opinion leader outreach and insights generation by proactively establishing and maintaining strong relationships with thought leaders, academic institutions, advocacy and medical societies in the field of oncology.
• Work closely with the Clinical, CRO, and future MSL teams to provide recruitment, scientific, and engagement support to facilitate clinical trial enrolment and timelines.
• Lead Patient Advocacy strategy and planning to incorporate the patient voice…